2013
Kirman CR, Aylward LL, Suh M , Harris MA, Thompson CM , Haws LC, Proctor DM, Lin SS, et al. 2013. Physiologically based pharmacokinetic model for humans orally exposed to chromium. Chem Biol Interact 204(1):13-27; doi: 10.1016/j.cbi.2013.04.003 . PMID: 23603453.
View Abstract
Publication: Manuscripts
O’Brien T, Ding H, Suh M , Thompson C , Parsons BL, Harris MA,…, Haws LC, Proctor DM. 2013. Assessment of K-Ras mutant frequency and micronucleus incidence in the mouse duodenum following 90-days of exposure to Cr(VI) in drinking water. Mutat Res 754(1-2):15-21. doi: 10.1016/j.mrgentox.2013.03.008 . PMID: 23583686.
View Abstract
Publication: Manuscripts
Suh M, Thompson CM , Harris MA. 2013. Mode of action evaluation for hexavalent chromium-induced lung cancer. Presented at Society of Toxicology 52nd Annual Meeting, March 10-14, San Antonio, TX.
View Abstract
Publication: Abstracts and Presentations
Suh M , Thompson CM , Hixon JG, Harris MA, Kirman CR, Hays S, Haws LC, Proctor DM. Potential involvement of oxidative stress and iron disturbance in the development of oral cavity tumors in rats exposed to hexavalent chromium. Presented at Society of Toxicology 52nd Annual Meeting, San Antonio, TX, March 2013.
View Abstract
Publication: Abstracts and Presentations
Kirman CR, Thompson CM , Proctor DM, Suh M , Haws LC, Harris MA, Hays SM. Using PBPK modeling to address diurnal variation and age differences in hexavalent chromium toxicokinetics in humans. Presented at Society of Toxicology 52nd Annual Meeting, San Antonio, TX, March 2013.
View Abstract
Publication: Abstracts and Presentations
Thompson CM , Kirman CR, Proctor DM, Suh M ,Hays SM, Haws LC, Harris MA. A chronic oral reference dose for hexavalent chromium. Presented at Society of Toxicology 52nd Annual Meeting, San Antonio, TX, March 2013.
View Abstract
Publication: Abstracts and Presentations
Thompson CM , Proctor DM, Suh M , Haws LC, Kirman CR, Harris MA. 2013. Assessment of the mode of action underlying development of rodent small intestinal tumors following oral exposure to hexavalent chromium and relevance to humans. Crit Rev Toxicol 43(3):244-274; doi: 10.3109/10408444.2013.768596 . PMID: 23445218.
View Abstract
Publication: Manuscripts
2012
Kirman CR, Hays SM, Aylward LL, Suh M , Harris MA, Thompson CM , Haws LC, Proctor DM. 2012. Physiologically based pharmacokinetic model for rats and mice orally exposed to chromium. Chem Biol Interact 200(1):45-64; doi: 10.1016/j.cbi.2012.08.016 . PMID: 22981460.
View Abstract
Publication: Manuscripts
Thompson CM , Hixon JG, Proctor DM, Haws LC, Suh M , Urban JD , Harris MA. 2012. Assessment of genotoxic potential of Cr(VI) in the mouse duodenum: An in silico comparison with mutagenic and nonmutagenic carcinogens across tissues. Regul Toxicol Pharmacol 64(1):68-76; doi: 10.1016/j.yrtph.2012.05.019 . PMID: 22705708.
View Abstract
Publication: Manuscripts
Proctor DM, Suh M , Aylward LL, Kirman CR, Harris MA, Thompson CM , Gürleyük H, Gerads R, Haws LC, Hays SM. 2012. Hexavalent chromium reduction kinetics in rodent stomach contents. Chemosphere 89(5):487-493; doi: 10.1016/j.chemosphere.2012.04.065 . PMID: 22682893.
View Abstract